We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
Veracyte's Afirma revenues rose 18% in Q2, with test volume up 10% to about 18,600.
Decipher revenues increased 20% to $91.9 million, while volume climbed 17% to about 29,700 tests.
Veracyte faces competitive, macro and cost pressures as it invests in products and clinical programs.
Veracyte (VCYT - Free Report) is well positioned for growth in the coming quarters, driven by continued sales momentum for its Afirma and Decipher Prostate tests. However, macroeconomic pressures and intense competition remain key concerns.
In the past year, this Zacks Rank #1 (Strong Buy) stock has risen 51.5% against the industry’s 3.4% decline. The S&P 500 composite has gained 20.5% in the same time frame.
The renowned diagnostics company has a market capitalization of $3.53 billion. The company’s earnings yield of 5.6% favorably compares to the industry’s -1% yield. Veracyte topped earnings estimates in each of the trailing four quarters, the average surprise being 45.9%.
Positives for VCYT Stock
Afirma Continues to Outperform: Veracyte’s comprehensive Afirma solution, which includes the Afirma GSC and Afirma Xpression Atlas, addresses the complexities of thyroid nodule diagnosis and is designed to deliver actionable results from a single fine-needle aspiration biopsy. Adoption has remained broad, with Afirma volume rising 10% to about 18,600 tests in the second quarter. Second-quarter 2026 revenues increased 18%, supported by higher utilization, share gains and better reimbursement.
The V2 transcriptome workflow continued to lower the no-result rate, contributing about 400 basis points to second-quarter volume growth by converting more low-input RNA samples into reportable results. The company now expects Afirma revenues to rise approximately 12% to 14% in 2026. Continued evidence generation, including 10 conference abstracts in the second quarter, supports the franchise’s ability to sustain adoption.
Strength of the Decipher Franchise: Decipher Prostate uses whole-transcriptome analysis and machine learning to help predict metastatic risk and guide treatment decisions across prostate cancer settings. In the second quarter of 2026, Decipher revenues increased 20% year over year to $91.9 million and volume rose 17% to approximately 29,700 tests. Orders per physician reached a record high, alongside an increase in the number of new ordering physicians.
Evidence generation remains central to the longer-term case. Decipher appeared in more than 35 publications and abstracts in the second quarter, including predictive evidence from the ENZAMET trial in metastatic prostate cancer. Additional studies in low-risk and active-surveillance populations are expected to begin reading out in 2027, creating a pathway to broaden clinical support over time.
What Ails VCYT Stock?
Competitive Landscape: Veracyte operates in markets where genomic diagnostics adoption is advancing and competitors continue to invest in alternative technologies and broader test menus. In thyroid testing, competitors include companies and academic institutions using next-generation sequencing or targeted mutation panels.
Intense competition may require continued investment in clinical evidence and commercialization to sustain adoption. Intellectual property disputes add another layer of execution risk. Veracyte’s patent case against Sonic Healthcare USA remains active, with a jury trial scheduled for the first quarter of 2027 after the court denied Sonic’s motion to dismiss and one asserted patent entered ex parte reexamination.
Image Source: Zacks Investment Research
Macro Issues Hurt Growth: Veracyte remains exposed to inflation, interest-rate volatility, foreign exchange movements, evolving trade policies and tariffs that can affect operating costs, payer behavior and testing demand. Geopolitical developments can also disrupt operations, including conditions in and around Israel, where the company has activities in Haifa. These risks come as Veracyte increases investment to support its core portfolio and new product launches.
In the second quarter of 2026, non-GAAP sales and marketing expense rose to $25.5 million from $23.1 million a year earlier, while non-GAAP R&D increased to $26.3 million from $14.3 million, reflecting both organizational changes and higher clinical and product investment. Continued cost discipline will be needed as these programs scale.
VCYT Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased 4.3% to $1.93.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $591.5 million, implying a 14.4% rise from the year-ago reported number.
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
Envista, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. NVST’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 19.4%.
Teleflex, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
Key Takeaways
Veracyte (VCYT - Free Report) is well positioned for growth in the coming quarters, driven by continued sales momentum for its Afirma and Decipher Prostate tests. However, macroeconomic pressures and intense competition remain key concerns.
In the past year, this Zacks Rank #1 (Strong Buy) stock has risen 51.5% against the industry’s 3.4% decline. The S&P 500 composite has gained 20.5% in the same time frame.
The renowned diagnostics company has a market capitalization of $3.53 billion. The company’s earnings yield of 5.6% favorably compares to the industry’s -1% yield. Veracyte topped earnings estimates in each of the trailing four quarters, the average surprise being 45.9%.
Positives for VCYT Stock
Afirma Continues to Outperform: Veracyte’s comprehensive Afirma solution, which includes the Afirma GSC and Afirma Xpression Atlas, addresses the complexities of thyroid nodule diagnosis and is designed to deliver actionable results from a single fine-needle aspiration biopsy. Adoption has remained broad, with Afirma volume rising 10% to about 18,600 tests in the second quarter. Second-quarter 2026 revenues increased 18%, supported by higher utilization, share gains and better reimbursement.
The V2 transcriptome workflow continued to lower the no-result rate, contributing about 400 basis points to second-quarter volume growth by converting more low-input RNA samples into reportable results. The company now expects Afirma revenues to rise approximately 12% to 14% in 2026. Continued evidence generation, including 10 conference abstracts in the second quarter, supports the franchise’s ability to sustain adoption.
Strength of the Decipher Franchise: Decipher Prostate uses whole-transcriptome analysis and machine learning to help predict metastatic risk and guide treatment decisions across prostate cancer settings. In the second quarter of 2026, Decipher revenues increased 20% year over year to $91.9 million and volume rose 17% to approximately 29,700 tests. Orders per physician reached a record high, alongside an increase in the number of new ordering physicians.
Evidence generation remains central to the longer-term case. Decipher appeared in more than 35 publications and abstracts in the second quarter, including predictive evidence from the ENZAMET trial in metastatic prostate cancer. Additional studies in low-risk and active-surveillance populations are expected to begin reading out in 2027, creating a pathway to broaden clinical support over time.
What Ails VCYT Stock?
Competitive Landscape: Veracyte operates in markets where genomic diagnostics adoption is advancing and competitors continue to invest in alternative technologies and broader test menus. In thyroid testing, competitors include companies and academic institutions using next-generation sequencing or targeted mutation panels.
Intense competition may require continued investment in clinical evidence and commercialization to sustain adoption. Intellectual property disputes add another layer of execution risk. Veracyte’s patent case against Sonic Healthcare USA remains active, with a jury trial scheduled for the first quarter of 2027 after the court denied Sonic’s motion to dismiss and one asserted patent entered ex parte reexamination.
Image Source: Zacks Investment Research
Macro Issues Hurt Growth: Veracyte remains exposed to inflation, interest-rate volatility, foreign exchange movements, evolving trade policies and tariffs that can affect operating costs, payer behavior and testing demand. Geopolitical developments can also disrupt operations, including conditions in and around Israel, where the company has activities in Haifa. These risks come as Veracyte increases investment to support its core portfolio and new product launches.
In the second quarter of 2026, non-GAAP sales and marketing expense rose to $25.5 million from $23.1 million a year earlier, while non-GAAP R&D increased to $26.3 million from $14.3 million, reflecting both organizational changes and higher clinical and product investment. Continued cost discipline will be needed as these programs scale.
VCYT Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased 4.3% to $1.93.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $591.5 million, implying a 14.4% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Envista (NVST - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Envista, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. NVST’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 19.4%.
Teleflex, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.